FR2787464B1 - PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS - Google Patents

PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS

Info

Publication number
FR2787464B1
FR2787464B1 FR9816145A FR9816145A FR2787464B1 FR 2787464 B1 FR2787464 B1 FR 2787464B1 FR 9816145 A FR9816145 A FR 9816145A FR 9816145 A FR9816145 A FR 9816145A FR 2787464 B1 FR2787464 B1 FR 2787464B1
Authority
FR
France
Prior art keywords
detection
treatment
pharmaceutical compositions
endothelial cells
particularly cancers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9816145A
Other languages
French (fr)
Other versions
FR2787464A1 (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROTECH
Original Assignee
NEUROTECH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NEUROTECH filed Critical NEUROTECH
Priority to FR9816145A priority Critical patent/FR2787464B1/en
Priority to PCT/FR1999/002965 priority patent/WO2000037112A1/en
Priority to JP2000589222A priority patent/JP2002532567A/en
Priority to EP99973474A priority patent/EP1140208A1/en
Priority to AU13924/00A priority patent/AU777526B2/en
Priority to CA002355879A priority patent/CA2355879A1/en
Publication of FR2787464A1 publication Critical patent/FR2787464A1/en
Application granted granted Critical
Publication of FR2787464B1 publication Critical patent/FR2787464B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR9816145A 1998-12-21 1998-12-21 PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS Expired - Fee Related FR2787464B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
FR9816145A FR2787464B1 (en) 1998-12-21 1998-12-21 PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS
PCT/FR1999/002965 WO2000037112A1 (en) 1998-12-21 1999-11-30 Pharmaceutical compositions comprising immortalised endothelial cells
JP2000589222A JP2002532567A (en) 1998-12-21 1999-11-30 Pharmaceutical composition containing immortalized endothelial cells
EP99973474A EP1140208A1 (en) 1998-12-21 1999-11-30 Pharmaceutical compositions comprising immortalised endothelial cells
AU13924/00A AU777526B2 (en) 1998-12-21 1999-11-30 Pharmaceutical compositions comprising immortalised endothelial cells
CA002355879A CA2355879A1 (en) 1998-12-21 1999-11-30 Pharmaceutical compositions comprising immortalised endothelial cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9816145A FR2787464B1 (en) 1998-12-21 1998-12-21 PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS

Publications (2)

Publication Number Publication Date
FR2787464A1 FR2787464A1 (en) 2000-06-23
FR2787464B1 true FR2787464B1 (en) 2003-01-10

Family

ID=9534247

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9816145A Expired - Fee Related FR2787464B1 (en) 1998-12-21 1998-12-21 PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS

Country Status (6)

Country Link
EP (1) EP1140208A1 (en)
JP (1) JP2002532567A (en)
AU (1) AU777526B2 (en)
CA (1) CA2355879A1 (en)
FR (1) FR2787464B1 (en)
WO (1) WO2000037112A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5432322B2 (en) * 2012-05-08 2014-03-05 株式会社大塚製薬工場 Mammalian cell suspension for prevention of pulmonary embolism containing trehalose

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017569A1 (en) * 1991-04-04 1992-10-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immortalization of endothelial cells
WO1993013807A1 (en) * 1992-01-10 1993-07-22 Georgetown University A method of administering genetically engineered endothelial cells to sites of angiogenesis for effecting genetic therapy
FR2726005B1 (en) * 1994-10-10 1997-01-03 Adim IMMORTALIZED LINES OF CEREBRAL ENDOTHELIAL CELLS AND THEIR APPLICATIONS FOR THE TREATMENT OF DIFFERENT NEUROLOGICAL OR PSYCHIATRIC PRIMARY AND SECONDARY DISORDERS OR DISEASES
JPH09173060A (en) * 1995-12-28 1997-07-08 Kiyuurin:Kk Establishment of cultured strain of immortalized human coronary arterial vascular endothelial cell and production of cardiovascular therapeutic agent using the same
FR2747690B1 (en) * 1996-04-19 1998-06-12 Neurotech Sa IMMORTALIZED RETINAL CELL LINES AND THEIR APPLICATIONS FOR THE TREATMENT OF DIFFERENT OPHTHALMOLOGICAL OR NEUROLOGICAL PRIMARY OR SECONDARY DISORDERS
EP0893493A3 (en) * 1997-07-21 2002-12-04 Aventis Pharma Deutschland GmbH Genetically modified cells and their use for prophylaxis or treatment of diseases

Also Published As

Publication number Publication date
AU777526B2 (en) 2004-10-21
JP2002532567A (en) 2002-10-02
WO2000037112A1 (en) 2000-06-29
FR2787464A1 (en) 2000-06-23
AU1392400A (en) 2000-07-12
CA2355879A1 (en) 2000-06-29
EP1140208A1 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
ATE246514T1 (en) MEDICINAL PRODUCTS CONTAINING PACLITAXEL
MA26654A1 (en) NEW PYRROLOPYRIMIDINES PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE69802260D1 (en) Pharmaceutical compositions containing Lactobacillus brevis and Lactobacillus salivarius for the treatment of vaginal infections
MA26935A1 (en) PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS
FR2722984B1 (en) PROCESS FOR THE PREPARATION OF DRY PHARMACEUTICAL FORMS AND THE PHARMACEUTICAL COMPOSITIONS THUS PRODUCED
ES2191102T3 (en) USEFUL PEPTIDYL HETEROCICLES IN THE TREATMENT OF THROMBIN-RELATED AFFECTIONS.
FR12C0077I2 (en) Composition for the treatment of genital warts
PT1189895E (en) TIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL UTILIZATION
MA26790A1 (en) DIETETIC OR PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF HYPER-OXALURIA
DE69928952D1 (en) CHINOLIN DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
PT1212317E (en) INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF OSTEOPOROSIS BETWEEN OTHER APPLICATIONS
PT902789E (en) ANDROSTENE DERIVATIVES
FR2786075B1 (en) SEALED PACKAGING FOR COSMETIC AND / OR PHARMACEUTICAL COMPOSITIONS
BR9609831A (en) Antipruritic cosmetic and / or pharmaceutical compositions
MA26618A1 (en) PHARMACEUTICAL COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MALARIA
PT929516E (en) BENZAMIDINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS WITH ANTAGONIST EFFECT OF LTB4
DE19580261D2 (en) Pharmaceutical preparations and drugs for the prevention and treatment of endothelial dysfunction
FR2802812B1 (en) USE OF RESIDUES FROM THE MANUFACTURE OF WINE FOR THE MANUFACTURE OF COSMETIC AND / OR PHARMACEUTICAL PREPARATIONS.
TR200000455T2 (en) The use of fanquinone in the treatment of Alzheimer's disease.
FR2787464B1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING IMMORTALIZED ENDOTHELIAL CELLS FOR THE DETECTION AND / OR TREATMENT OF ANGIOGENIC SOURCES AND PARTICULARLY CANCERS
FR2736056B1 (en) CYCLODEXTRIN DERIVATIVES, THEIR PREPARATION AND THEIR USE FOR INCORPORATING HYDROPHOBIC MOLECULES IN ORGANIZED SURFACTANT SYSTEMS
FR2756735B1 (en) AGENT FOR INHIBITING THE EXPRESSION OF THE ICAM-1 ADHESION PROTEIN AND COSMETIC AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP1218705A4 (en) High-volume on-line spectroscopic composition testing of manufactured pharmaceutical dosage units
FR2756736B1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING N-SULFONYL INDOLINE DERIVATIVES
MA26650A1 (en) OXO-THIA -AZABICYCLOOCTENES, PHARMACEUTICAL PREPARATIONS CONTAINING THEM, AND THEIR USE FOR THE TREATMENT AND PROPHYLAXIS OF INFECTIOUS DISEASES.

Legal Events

Date Code Title Description
ST Notification of lapse